 |
|
Shire investigational drug (SPD465) designed to reduce ADHD symptoms for up to 16 hours
November 01, 2006Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) announced the results of two phase II trials in adults (studies 201 and 203) of the investigational amphetamine compound SPD465 (triple-bead mixed amphetamine salts [MAS]) at a major medical meeting of child and adolescent psychiatrists in San Diego, Calif. These results demonstrated that SPD465 improved Attention-Deficit/Hyperactivity Disorder (ADHD) symptoms in adults for up to 16 hours post-dose and had a generally well tolerated safety profile consistent with currently marketed amphetamine products.
"If approved, triple-bead MAS may be useful for maintaining adult ADHD symptom control throughout the day and during the evening hours, at work or at home, due to its long duration of action," said Timothy Wigal, Ph.D., lead investigator for both studies and associate clinical professor of pediatrics and deputy director of the Child Development Center at the University of California, Irvine.
On July 21, 2006, Shire submitted a New Drug Application for triple-bead MAS, which is now under FDA review. If approved, triple-bead MAS would be the first and only ADHD stimulant product designed to control inattention, hyperactivity and impulsivity in adults for up to 16 hours with one daily dose. More than 9 million American adults currently exhibit symptoms of ADHD.
Study 203: Single Morning Dose of Triple-bead MAS 25 mg In this study of 73 adult subjects, those taking the 25 mg dose had significantly higher scores than subjects taking placebo as measured by the Permanent Product Measure of Performance (PERMP), the primary endpoint, at 16-hours post-dose (P < .0001). This test is a 10-minute, written, age-adjusted collection of 80 math problems that provides an accurate measure of a person's ability to pay attention and stay on task. Subanalyses of the number of problems attempted and the number answered correctly showed similar results.
In addition, subjects treated with triple-bead MAS had significantly improved average ADHD Rating Scale (ADHD-SRS) total scores than those taking placebo (P < .0001) at all test times (5.5, 11 and 16.5 hours) post-dose.
Study 201: This study evaluated 77 adult subjects with ADHD during three seven-day treatment periods at doses of 50 mg or 75 mg of triple-bead MAS compared to placebo, and used an active control for test sensitivity. The study results demonstrated that triple-bead MAS provided significant improvement in ADHD symptom control based on PERMP and ADHD-RS scores.
With both triple-bead MAS doses, the average PERMP total, attempted and correct scores were significantly better than with placebo at all times measured after dosing. Average ADHD-SRS total scores were significantly better for participants receiving triple-bead MAS than those taking placebo (P < .0001) at all three test times (5.5, 11.0 and 16.5 hours) post-dose.
Triple-bead MAS was generally well tolerated in both studies, although two serious adverse events, chest pain with no sequelae and hypertension with no sequelae, were reported in subjects treated with 75 mg. The most frequently reported adverse events in both studies were insomnia, decreased appetite, dry mouth, headache and anorexia and were consistent with amphetamine use.
Shire Development Inc. supported these studies.
About ADHD Approximately 7.8 percent of all school-age children, or about 4.4 million U.S. children aged 4 to 17 years, have been diagnosed with ADHD at some point in their lives, according to the U.S. Centers for Disease Control and Prevention (CDC). ADHD is one of the most common psychiatric disorders in children and adolescents. ADHD is a neurobiological psychiatric disorder that manifests as a persistent pattern of inattention and/or hyperactivity-impulsivity that is more frequent and severe than is typically observed in individuals at a comparable level of development. A diagnosis of Attention-Deficit/Hyperactivity Disorder in adults (ADHD; DSM-IV) implies the presence of hyperactive-impulsive and/or inattentive symptoms that cause impairment and were present before the age of 7 years. The symptoms must cause clinically significant impairment, e.g., in social, academic, or occupational functioning, and be present in two or more settings, e.g., school (or work) and at home. The symptoms must not be better accounted for by another mental disorder.
Although there is no "cure" for ADHD, there are accepted treatments that specifically target its symptoms. The most common standard treatments include educational approaches, psychological or behavioral modification, and medication.
Porter Novelli
Study 203: Single Morning Dose of Triple-bead MAS 25 mg In this study of 73 adult subjects, those taking the 25 mg dose had significantly higher scores than subjects taking placebo as measured by the Permanent Product Measure of Performance (PERMP), the primary endpoint, at 16-hours post-dose (P < .0001). This test is a 10-minute, written, age-adjusted collection of 80 math problems that provides an accurate measure of a person's ability to pay attention and stay on task. Subanalyses of the number of problems attempted and the number answered correctly showed similar results.
In addition, subjects treated with triple-bead MAS had significantly improved average ADHD Rating Scale (ADHD-SRS) total scores than those taking placebo (P < .0001) at all test times (5.5, 11 and 16.5 hours) post-dose.
Study 201: This study evaluated 77 adult subjects with ADHD during three seven-day treatment periods at doses of 50 mg or 75 mg of triple-bead MAS compared to placebo, and used an active control for test sensitivity. The study results demonstrated that triple-bead MAS provided significant improvement in ADHD symptom control based on PERMP and ADHD-RS scores.
With both triple-bead MAS doses, the average PERMP total, attempted and correct scores were significantly better than with placebo at all times measured after dosing. Average ADHD-SRS total scores were significantly better for participants receiving triple-bead MAS than those taking placebo (P < .0001) at all three test times (5.5, 11.0 and 16.5 hours) post-dose.
Triple-bead MAS was generally well tolerated in both studies, although two serious adverse events, chest pain with no sequelae and hypertension with no sequelae, were reported in subjects treated with 75 mg. The most frequently reported adverse events in both studies were insomnia, decreased appetite, dry mouth, headache and anorexia and were consistent with amphetamine use.
Shire Development Inc. supported these studies.
About ADHD Approximately 7.8 percent of all school-age children, or about 4.4 million U.S. children aged 4 to 17 years, have been diagnosed with ADHD at some point in their lives, according to the U.S. Centers for Disease Control and Prevention (CDC). ADHD is one of the most common psychiatric disorders in children and adolescents. ADHD is a neurobiological psychiatric disorder that manifests as a persistent pattern of inattention and/or hyperactivity-impulsivity that is more frequent and severe than is typically observed in individuals at a comparable level of development. A diagnosis of Attention-Deficit/Hyperactivity Disorder in adults (ADHD; DSM-IV) implies the presence of hyperactive-impulsive and/or inattentive symptoms that cause impairment and were present before the age of 7 years. The symptoms must cause clinically significant impairment, e.g., in social, academic, or occupational functioning, and be present in two or more settings, e.g., school (or work) and at home. The symptoms must not be better accounted for by another mental disorder.
Although there is no "cure" for ADHD, there are accepted treatments that specifically target its symptoms. The most common standard treatments include educational approaches, psychological or behavioral modification, and medication.
Porter Novelli
Adhd News and Current Adhd Events RSSStudy examines relationship between low birth weight and psychiatric problems in children
Low-birth-weight children appear to be at higher risk for psychiatric disturbances from childhood through high school than normal-birth-weight children, according to a report in the September issue of Archives of General Psychiatry, one of the JAMA/Archives journals.
Barrow scientists work their magic
Two neuroscientists at Barrow Neurological Institute at St. Joseph's Hospital and Medical Center are turning magic tricks into science.
APA task force recommends dissemination of evidence-based practice
An estimated 15 million American children are diagnosed with a mental disorder, but only about a quarter of them are getting appropriate treatment based on scientific evidence.
Innovative program focuses on improved care for children with ADHD
An innovative program is helping busy primary care physicians improve the care they provide for school-aged children with Attention-Deficit/Hyperactivity Disorder (ADHD), according to a study led by researchers at Cincinnati Children's Hospital Medical Center and published in the July edition of Pediatrics.
Did the gene for ADHD help our nomadic ancestors?
An ADHD-associated version of the human gene DRD4 is linked to better health among nomadic tribesmen, but may cause malnourishment in their settled cousins, according to new research by a team directed by an anthropologist at the University of Wisconsin-Milwaukee (UWM).
PET imaging focuses on medication's purported ability to improve mental performance
Concerned by the growing numbers of people using stimulant medications such as methylphenidate (MP)-either legally or illegally-to improve attention and focus, researchers used positron emission tomography (PET) imaging with the radiotracer fluorodeoxyglucose (FDG) to assess the effects of the drug on brain function in the normal human brain.
Knowing looks: Using gaze aversion to tell when children are learning
People use eye contact in a variety of ways every minute of every day but how often do you find yourself staring into space with concentrating on an issue or problem? Psychologists now know that people who are carrying out a complex task tend to look away from anyone else who is nearby. They refer to it as 'gaze aversion'.
Report confirms increased risk of smoking, substance abuse in bipolar adolescents
A study from the Massachusetts General Hospital (MGH) supports previous reports that adolescents with bipolar disorder are at increased risk for smoking and substance abuse.
Children's diet not the main cause of ADHD
Food may not be the major cause of hyperactivity in children. Genetics, brain function and parental actions such as smoking may be just as important.
A trial of removing food additives should be considered for hyperactive children
A properly supervised trial eliminating colours and preservatives from the diet of hyperactive children should considered a part of the standard treatment, says an editorial in this week's BMJ.
More Adhd News Articles
 | Change Your Brain, Change Your Life: The Breakthrough Program for Conquering Anxiety, Depression, Obsessiveness, Anger, and Impulsiveness by Daniel G. Amen In this age of do-it-yourself health care (heck, if the doctor only sees you for 10 minutes each visit, what other options are there?), Change Your Brain, Change Your Life fits in perfectly. Filled with "brain prescriptions" (among them cognitive exercises and nutritional advice) that are geared toward readers who've experienced anxiety, depression, impulsiveness, excessive anger or worry, and... |
 | Driven To Distraction : Recognizing and Coping with Attention Deficit Disorder from Childhood Through Adulthood by Edward M. Hallowell, John J. Ratey This clear and valuable book dispels a variety of myths about attention deficit disorder (ADD). Since both authors have ADD themselves, and both are successful medical professionals, perhaps there's no surprise that the two myths they attack most persistently are: (a) that ADD is an issue only for children; and (b) that ADD corresponds simply to limited intelligence or limited self-discipline.... |
 | The Out-of-Sync Child: Recognizing and Coping with Sensory Processing Disorder, Revised Edition by Carol Stock Kranowitz NEWLY REVISED AND UPDATED The Out-of-Sync Child broke new ground by identifying Sensory Processing Disorder, a common but frequently misdiagnosed problem in which the central nervous system misinterprets messages from the senses. This newly revised edition features additional information from recent research on vision and hearing deficits, motor skill problems, nutrition and picky eaters, ADHA,... |
 | Delivered from Distraction: Getting the Most out of Life with Attention Deficit Disorder by Edward M. Md Hallowell, John J. Md Ratey Medication? Maybe. Marry the right person and find the right job? A must if you are an adult suffering from ADD (Attention Deficit Disorder). So say psychiatrists Edward M. Hallowell and John J. Ratey, authors of the influential Driven to Distraction, published in 1994. In their new book, Delivered from Distraction, Hallowell and Ratey survey the current medical landscape concerning ADD,... |
 | Healing ADD: The Breakthrough Program That Allows You to See and Heal the 6 Types of ADD by Daniel G. Amen Hard, visual data make a compelling case for the existence of attention deficit disorder (ADD) in this pioneering work by Daniel G. Amen, M.D. Using a nuclear medicine technique called "single photon emission computed tomography" (SPECT)--a controversial step, according to some of his peers--Dr. Amen scans patients' brains to identify various abnormalities. From more than 8,000 such studies and... |
 | ADD-Friendly Ways to Organize Your Life by Judith Kolberg, Kathleen Nadeau Organizing books fall short of addressing the unique needs of adults with ADD. They fail to understand the clinical picture of ADD and how it impacts the organizing process often making their advice irrelevant or frustrating when put into application. Books about ADD may address organization/disorganization but do so in a cursory fashion and on a very small scale in what are usually long books... |
 | Screamfree Parenting: The Revolutionary Approach to Raising Your Kids by Keeping Your Cool by Hal Edward Runkel You Can Start a Revolution in Your Family . . . TonightScreamFree Parenting is not just about lowering your voice. It’s about learning to calm your emotional reactions and learning to focus on your own behavior more than your kids’ behavior . . . for their benefit. Our biggest enemy as parents is not the TV, the Internet, or even drugs. Our biggest enemy is our own emotional... |
 | Healing the New Childhood Epidemics: Autism, ADHD, Asthma, and Allergies: The Groundbreaking Program for the 4-A Disorders by Kenneth Bock, Cameron Stauth Autism is an epidemic: It has spiked 1,500 percent in the last twenty years. ADHD, asthma and allergies have also skyrocketed over the same time period. One of these conditions now strikes one in every three children in America. But there is hope. Leading medical innovator Kenneth Bock, M.D., has helped change the lives of more than a thousand children, and in this important book, with a... |
 | 10 Days to a Less Defiant Child: The Breakthrough Program for Overcoming Your Child's Difficult Behavior by Jeffrey Bernstein Occasional clashes between parents and children are not uncommon, but when defiant behavior — such as tantrums, resistance to chores, and negativity — becomes chronic, it can cause big problems within the family. In 10 Days to a Less Defiant Child, child and family psychologist Dr. Jeff Bernstein has developed a ground-breaking 10-day program to help parents gain back control over... |
 | You Mean I'm Not Lazy, Stupid or Crazy?!: The Classic Self-Help Book for Adults with Attention Deficit Disorder by Kate Kelly, Peggy Ramundo With over a quarter million copies in print, You Mean I'm Not Lazy, Stupid or Crazy?! is one of the bestselling books on attention deficit disorder (ADD) ever written. There is a great deal of literature about children with ADD. But what do you do if you have ADD and aren't a child anymore? This indispensable reference -- the first of its kind written for adults with ADD by adults with ADD --... |
| © 2008 BrightSurf.com |